Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 12/20 | 0.62 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.53 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.52 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1373888 | 1.00 | LTA4H (0.62) | LTA4HS1PR1NPY5RSPHK1SPHK2 | |
| SCHEMBL1371813 | 0.93 | LTA4H (0.57) | LTA4HS1PR1SPHK1SPHK2 | |
| SCHEMBL1371811 | 0.93 | LTA4H (0.57) | LTA4HS1PR1SPHK1SPHK2 | |
| SCHEMBL1375610 | 0.85 | LTA4H (0.56) | LTA4HS1PR1NPY5R | |
| SCHEMBL1375609 | 0.85 | LTA4H (0.56) | LTA4HS1PR1NPY5R | |
| SCHEMBL27858267 | 0.85 | LTA4H (0.56) | LTA4HNPY5R | |
| SCHEMBL20253481 | 0.82 | LTA4H (0.66) | LTA4HS1PR1 | |
| SCHEMBL20238754 | 0.82 | LTA4H (0.66) | LTA4HS1PR1 | |
| SCHEMBL1372073 | 0.80 | S1PR1 (0.62) | LTA4HS1PR1 | |
| SCHEMBL1372071 | 0.80 | S1PR1 (0.62) | LTA4HS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | LTA4H 1113/4885S1PR1 1/4885NPY5R 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.